See also:

CORONA study, 2007	TRC6786
[NCT00206310]	download pdf: rosuvastatin | cholesterol lowering intervention for heart failure

Treatments

Studied treatment	rosuvastatin 10mg/d
Control treatment	placebo

Patients

Patients

patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failure

Method and design

Randomized effectives	2514 / 2497 (studied vs. control)
Design	Parallel groups
Blinding	double blind
Follow-up duration	32.9 months median
Primary endpoint	cardiovascular death, MI, stroke

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

new-onset diabetes

100 / 1771
88 / 1763
1,13 [0,86;1,49]

Non fatal MI

115 / 2514
141 / 2497
0,81 [0,64;1,03]

Fatal stroke

35 / 2514
32 / 2497
1,09 [0,67;1,75]

Cardiovascular death

488 / 2514
487 / 2497
1,00 [0,89;1,11]

Coronary event

554 / 2514
588 / 2497
0,94 [0,85;1,04]

Non vascular death

138 / 2514
159 / 2497
0,86 [0,69;1,08]

cardiovascular events

692 / 2514
732 / 2497
0,94 [0,86;1,03]

All cause death

728 / 2514
759 / 2497
0,95 [0,87;1,04]

Fatal MI

15 / 2514
9 / 2497
classic 1,66 [0,73;3,78]

Non fatal stroke

89 / 2514
104 / 2497
0,85 [0,64;1,12] 0 2 1.0

Relative risks
Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
	Studied treat.	Control treat.
new-onset diabetes	100 / 1771 (5,6%)	88 / 1763 (5,0%)	1,13	[0,86;1,49]	sub group
Non fatal MI	115 / 2514 (4,6%)	141 / 2497 (5,6%)	0,81	[0,64;1,03]
Fatal stroke	35 / 2514 (1,4%)	32 / 2497 (1,3%)	1,09	[0,67;1,75]
Cardiovascular death	488 / 2514 (19,4%)	487 / 2497 (19,5%)	1,00	[0,89;1,11]
Coronary event	554 / 2514 (22,0%)	588 / 2497 (23,5%)	0,94	[0,85;1,04]
Non vascular death	138 / 2514 (5,5%)	159 / 2497 (6,4%)	0,86	[0,69;1,08]
cardiovascular events	692 / 2514 (27,5%)	732 / 2497 (29,3%)	0,94	[0,86;1,03]
All cause death	728 / 2514 (29,0%)	759 / 2497 (30,4%)	0,95	[0,87;1,04]
Fatal MI	15 / 2514 (0,6%)	9 / 2497 (0,4%)	1,66	[0,73;3,78]
Non fatal stroke	89 / 2514 (3,5%)	104 / 2497 (4,2%)	0,85	[0,64;1,12]
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 0: 11590: Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, Vetrovec GWMeta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure.Am J Cardiol 2009;104:1708-16

Endpoint	studied treat.	control treat.	mean diff

Absolute risk reduction (for a follow-up of 32.9 months median)
Endpoint	Events rate		Absolute risk reduction (ARR)
	Studied treat.	Control treat.
new-onset diabetes	5,65%	4,99%	0,66%
Non fatal MI	4,57%	5,65%	-1,07%
Fatal stroke	1,39%	1,28%	0,11%
Cardiovascular death	19,41%	19,50%	-0,09%
Coronary event	22,04%	23,55%	-1,51%
Non vascular death	5,49%	6,37%	-0,88%
cardiovascular events	27,53%	29,32%	-1,79%
All cause death	28,96%	30,40%	-1,44%
Fatal MI	5,97‰	3,60‰	0,24%
Non fatal stroke	3,54%	4,16%	-0,62%

Meta-analysis of all similar trials:

cholesterol lowering intervention in cardiovascular prevention for all chronical situations

cholesterol lowering intervention in heart failure for all type of patients

cholesterol lowering intervention in heart failure for elderly

Reference(s)

TrialResults-center ID	TRC6786
Trials register #	NCT00206310
Study web site link	,

• Kjekshus J, Apetrei E, Barrios V, B�hm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, J�nosi A, Kamensk� G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberg. Rosuvastatin in older patients with systolic heart failure.. N Engl J Med 2007;357:2248-61
  Pubmed | Hubmed | Fulltext

(c) 2004-2016 TrialResults-center - All Rights Reserved